Reset filter
Nyckelord
Orzecznictwo lekarskie ×
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Klinisk studie
  2. 2. Rutindokumentation
  3. 3. Register- och kohortstudier
  4. 4. Kvalitetssäkring
  5. 5. Datastandard
  6. 6. Frågeformulär för patienter
  7. 7. Medicinsk specialitet
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

9670 Sökresultat.
Relevans Bedömning Nya först Gamla först

Visit 1 Run - Inclusion Criteria NCT01117584

- 2017-01-28 - 1 Formulär, 1 Item-grupp, 3 Dataelement, 1 Språk
Item-grupp: Inclusion Criteria
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Eligibility Criteria: CRF Wisconsin Madison

- 2016-11-17 - 1 Formulär, 4 Item-grupper, 14 Dataelement, 1 Språk
Item-grupper: Header, Eligibility Criteria - Inclusion Criteria, Eligibility Criteria - Exclusion Criteria, undefined itemgroup
ODM Form derived from: https://ictr.wisc.edu/CaseReptTempt. Template Name: Eligibility Criteria. Case Report Form (CRF)/Source Document templates were created for University of Wisconsin-Madison researchers. These templates are consistent with the FDA's CDASH (Clinical Data Acquisition Standards Harmonization) standards. The CDASH standards identify those elements that should be captured on a Case Report Form (CRF). The forms serve only as templates, and must be edited to meet the study data collection needs as described in the protocol.

Immunogenicity of co-administration of Tritanrix™-HepB and DTPw-HBV vaccines or Triple Antigen™ and Engerix™-B with HRV vaccine to infants (3, 4½ and 6 month) - 104021 - Elimination Criteria (Study Eligibility)

- 2018-11-28 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Elimination Criteria during the Study
Study ID: 104021 Clinical Study ID: 104021 Study Title: A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158756 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix B Study Indication: Hepatitis B

Inclusion/Exclusion Criteria: UIC Quality Improvement CRF

- 2016-08-11 - 1 Formulär, 4 Item-grupper, 13 Dataelement, 1 Språk
Item-grupper: General Information, Inclusion Criteria, Exclusion Criteria, Results
ODM derived from: http://research.uic.edu/qip/toolbox/case-report-forms-crf. Template Name: Inclusion/Exclusion Criteria. QIP Case Report Forms, UIC Quality Improvement CRF, Office of the Vice Chancellor for Research. Center for Clinical and Translational Science, UIC University of Illinois at Chicago.

Eligibility Inflammatory Bowel Disease NCT01464151

- 2018-08-31 - 1 Formulär, 2 Item-grupper, 11 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study; ODM derived from: https://clinicaltrials.gov/show/NCT01464151 Sponsor: UMC Utrecht Collaborators: Merck Sharp & Dohme Corp. Ferring Pharmaceuticals Information provided by (Responsible Party): B. Oldenburg, UMC Utrecht

Estimation of Dose Proportionality of Darapladib - 107038 - Eligibility Question

- 2018-11-12 - 1 Formulär, 1 Item-grupp, 2 Dataelement, 1 Språk
Item-grupp: Eligibility Question
Study ID: 107038 Clinical Study ID: LPL107038 Study Title: Study to Estimate the Dose Proportionality of the Enteric-Coated Freebase Formulation of SB-480848 Patient Level Data:  Clinicaltrials.gov Identifier:  Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: Tyrisa ,US Study Indication: Atherosclerosis

DELCODE: DZNE – Longitudinal Cognitive Impairment and Dementia Study - Eligibility criteria (Ein- und Ausschlusskriterien)

- 2020-04-08 - 1 Formulär, 3 Item-grupper, 23 Dataelement, 1 Språk
Item-grupper: Administrative Data, Inclusion criteria, Exclusion criteria
DELCODE is conducted by DZNE, the German Center for Neurodegenerative Diseases within the Helmholtz Association. The following information was taken from https://www.dzne.de/en/research/studies/clinical-studies/delcode/. Background and aims: One of the important aims of research into Alzheimer's is to find ways of detecting the disease early – if at all possible, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Such detection capabilities are the necessary basis for development of therapies that can be applied at such early stages in the disease. Recent research indicates that such therapies could be more effective than therapies initiated during the disease's later stages. Over a period of several years, the DELCODE study is studying persons in early stages of the disease, along with various risk groups. The research is aimed at the development of procedures for characterizing early stages of the disease, at improving prediction of the course of the disease and at identifying new markers for early diagnosis of Alzheimer's-related dementia. Overview: DELCODE is set up to run for an initial period of three years, and to include a total of 1,000 study participants, who will be examined on a yearly basis. The group of participants will include persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer's disease. The minimum age for participants is 60. Course of the study: The examinations in the framework of the study will include a comprehensive interview carried out by a study investigator, a detailed neuropsychological examination (testing of memory functions and other areas of cognitive performance), a blood test and a cranial MRI scan. Optionally, subject to the study participant's consent in each case, a lumbar puncture (collection of cerebrospinal fluid) will be carried out." For more information (e.g. principle investigator and study coordination), please visit the above link or https://www.dzne.de. This document contains the Eligibility criteria. It has to be filled in at the baseline of the study.

Visit 1 inclusion/exclusion criteria starting dose of ropinirole Ropinirole Case Report Form GSK RRL100013

- 2021-09-20 - 1 Formulär, 3 Item-grupper, 28 Dataelement, 1 Språk
Item-grupper: administrative data, Inclusion criteria, exclusion criteria
Inclusion/exclusion criteria Ropinirole Case Report Form GSK Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

Exclusion Criteria second visit Ropinirole Case Report Form GSK RRL100013

- 2017-10-05 - 1 Formulär, 2 Item-grupper, 11 Dataelement, 1 Språk
Item-grupper: Administrative documentation, Exclusion Criteria
Exclusion Criteria second visit Ropinirole Case Report Form Concomitant Medication Ropinirole Case Report Form GSK Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

Exclusion Criteria 1 Ropinirole Case Report Form GSK RRL100013

- 2017-10-05 - 1 Formulär, 2 Item-grupper, 11 Dataelement, 1 Språk
Item-grupper: Administrative documentation, Exclusion Criteria
Exclusion Criteria 1 Ropinirole Case Report Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

Inclusion Ropinirole Case Report Form GSK RRL10001

- 2017-10-05 - 1 Formulär, 1 Item-grupp, 7 Dataelement, 1 Språk
Item-grupp: Inclusion Criteria
Inclusion Ropinirole Case Report Form Concomitant Medication Ropinirole Case Report Form GSK Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

Eligibility Question Ropinirole Case Report Form GSK RRL100013

- 2017-09-30 - 1 Formulär, 3 Item-grupper, 21 Dataelement, 1 Språk
Item-grupper: Eligibility Question, Inclusion Criteria, Exclusion Criteria
Eligibility Question Ropinirole Case Report Form GSK Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial